Krensavage Asset Management, LLC

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Krensavage Asset Management, LLC reported 18 stock positions worth $263.2 million. Its top holding was Enanta Pharmaceuticals (ENTA) at 15.9% of the portfolio, followed by Jazz Pharmaceuticals (JAZZ, 15.4%) and United Therapeutics (UTHR, 14.3%). Compared with Q1 2026, it sold out of 2, added to 4 and reduced 2. The biggest buy was Abbott Laboratories (ABT, shares +3900%) and the biggest sale United Therapeutics (UTHR, shares −18%).

Most Recent 13F
Q2 2026
Location
NEW YORK, NY
CIK
0001609251
Portfolio Value
$263.2M (Q2 2026)
SEC Filing
0001609251-26-000005 ↗ filed Aug 14, 2026

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $225.5M Q1 2024 Q2 2024: $217.8M Q2 2024 Q3 2024: $178.5M Q3 2024 Q4 2024: $169.0M Q4 2024 Q1 2025: $180.9M Q1 2025 Q2 2025: $188.9M Q2 2025 Q3 2025: $234.7M Q3 2025 Q4 2025: $283.1M Q4 2025 Q1 2026: $255.7M Q1 2026 Q2 2026: $263.2M $263.2M Q2 2026

Holdings 18 stocks · $263.2M
ENTA Enanta Pharmaceuticals Inc. 15.88% 2,866,138 $41.8M No change
JAZZ Jazz Pharmaceuticals PLC 15.36% 167,816 $40.4M No change
UTHR United Therapeutics Corp. 14.26% 69,282 $37.5M Reduce -17.8%
BMRN Biomarin Pharmaceutical Inc. 11.41% 524,786 $30.0M No change
EXEL Exelixis Inc. 7.66% 370,693 $20.2M Reduce -10.8%
ABT Abbott Laboratories 6.89% 200,000 $18.1M Add +3900.0%
SNY Sanofi-ADR 5.25% 323,946 $13.8M No change
SUPN Supernus Pharmaceuticals Inc. 4.96% 280,681 $13.1M No change
RARE Ultragenyx Pharmaceutical Inc. 4.96% 390,879 $13.1M No change
VNDA Vanda Pharmaceuticals Inc. 2.74% 1,180,388 $7.2M No change
BNTX Biontech SE-ADR 2.10% 59,523 $5.5M No change
GSK GSK PLC-Spon ADR 1.93% 96,729 $5.1M No change
BIIB Biogen Inc. 1.64% 20,000 $4.3M No change
REGN Regeneron Pharmaceuticals 1.42% 6,000 $3.7M Add +50.0%
EMBC Embecta Corp. 1.41% 1,135,340 $3.7M Add +54.4%
ARDX Ardelyx Inc. 1.04% 534,523 $2.7M Add +6.9%
INMD Inmode Ltd. 0.67% 120,942 $1.8M No change
EOLS Evolus Inc. 0.42% 157,985 $1.1M No change

Portfolio Sells Q1 2026 → Q2 2026
UTHR United Therapeutics Corp. Reduce -17.8% 14.26% −5.28
INDV Indivior Pharmaceuticals Inc. Sold out 0.00% −4.05
ALKS Alkermes PLC Sold out 0.00% −1.49
EXEL Exelixis Inc. Reduce -10.8% 7.66% +0.69

Portfolio Buys Q1 2026 → Q2 2026
ABT Abbott Laboratories Add +3900.0% 6.89% +6.69
REGN Regeneron Pharmaceuticals Add +50.0% 1.42% +0.21
ARDX Ardelyx Inc. Add +6.9% 1.04% −0.14
EMBC Embecta Corp. Add +54.4% 1.41% −1.14

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 18$263.2MENTA, JAZZ, UTHR, BMRN, EXEL
Q1 2026 20$255.7MUTHR, ENTA, JAZZ, BMRN, EXEL
Q4 2025 18$283.1MUTHR, ENTA, BMRN, JAZZ, EXEL
Q3 2025 17$234.7MUTHR, ENTA, JAZZ, BMRN, EXEL
Q2 2025 15$188.9MUTHR, CAH, EXEL, JAZZ, ENTA
Q1 2025 14$180.9MEXEL, UTHR, CAH, SUPN, JAZZ
Q4 2024Amended 12$169.0MUTHR, EXEL, CAH, BIIB, JAZZ
Q3 2024 13$178.5MUTHR, EXEL, CAH, BIIB, ENTA
Q2 2024 13$217.8MEXEL, UTHR, BIIB, TARO, CAH
Q1 2024 12$225.5MEXEL, UTHR, BIIB, TARO, CAH